Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 6:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Intravenous levetiracetam Clear all
Completed Phase 2 Interventional Results available

Open-label Study of Levetiracetam Intravenous Infusion in Children (4-16 Years Old) With Epilepsy

NCT00535392
View directory record Official record
Conditions
Epilepsy
Interventions
Levetiracetam
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
4 Years to 16 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
9
States / cities
La Jolla, California • Boston, Massachusetts • Chesterfield, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2011 · Synced Sep 23, 2026, 6:19 PM EDT
Completed Phase 4 Interventional Results available

Seizure Prophylaxis in Aneurysm Repair

NCT01801072
View directory record Official record
Conditions
Intracranial Aneurysms, Seizure
Interventions
Levetiracetam
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 23, 2026, 6:19 PM EDT
Terminated Not applicable Interventional Results available

Busulfan and Cyclophosphamide Followed By ALLO BMT

NCT01685411
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Allopurinol, Keppra, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Allogeneic hematopoietic stem cell transplant, Filgrastim, antithymocyte globulin
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 44 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 23, 2026, 6:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers

NCT02602860
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[11C]UCB-J, Brivaracetam, Levetiracetam
Radiation · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 29, 2017 · Synced Sep 23, 2026, 6:19 PM EDT
Completed Phase 2 Interventional

Levetiracetam Treatment of L-dopa Induced Dyskinesias

NCT00076674
View directory record Official record
Conditions
Dyskinesias, Parkinson Disease
Interventions
Intravenous Levodopa
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Sep 23, 2026, 6:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy of Intravenous Levetiracetam in Neonatal Seizures

NCT01720667
View directory record Official record
Conditions
Neonatal Seizures
Interventions
Intravenous levetiracetam, Intravenous phenobarbital
Drug
Lead sponsor
Richard H. Haas
Other
Eligibility
15 Minutes to 14 Days
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Sep 23, 2026, 6:19 PM EDT
Completed Phase 2Phase 3 Interventional

Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint

NCT03580707
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
BRV vs LEV in randomized double blinded, crossover fashion
Drug
Lead sponsor
Rosenfeld, William E., M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 23, 2026, 6:19 PM EDT
Terminated Phase 4 Interventional Results available

Antiseizure Medication in Seizure Networks at Early Acute Brain Injury

NCT06081283
View directory record Official record
Conditions
Brain Injuries, Acute, Brain Injuries, Traumatic, Brain Ischemia, Brain Hypoxia, Hypoxia-Ischemia, Brain, Heart Arrest, Stroke, Intracranial Hemorrhages, Coma, Persistent Vegetative State
Interventions
Phenobarbital Sodium Injection, Levetiracetam, Lacosamide Injectable Product, Valproate Sodium, Fosphenytoin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Months to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 23, 2026, 6:19 PM EDT
Recruiting Phase 2 Interventional

A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures

NCT05610085
View directory record Official record
Conditions
Neonatal Seizure, Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy, Seizure Newborn
Interventions
Levetiracetam Injection, Phenobarbital Sodium Injection
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 1 Month
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
San Diego, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 23, 2026, 6:19 PM EDT
Completed Phase 4 Interventional Results available

Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention

NCT00618436
View directory record Official record
Conditions
Traumatic Brain Injury, Subarachnoid Hemorrhage
Interventions
Levetiracetam, Phenytoin
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2014 · Synced Sep 23, 2026, 6:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma

NCT00404248
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
terameprocol, pharmacological study
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 23, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available

Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy

NCT00505934
View directory record Official record
Conditions
Epilepsy
Interventions
Levetiracetam
Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
1 Month to 4 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
San Diego, California • Buffalo, New York • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Sep 23, 2026, 6:19 PM EDT
Recruiting Phase 2 Interventional

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

NCT05735717
View directory record Official record
Conditions
Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, AML, TP53, Intrachromosomal Amplification of Chromosome 21, Cytogenetic Abnormality, CNS Leukemia, Minimal Residual Disease, Myelodysplasia, Juvenile Myelomonocytic Leukemia, Somatic Mutation, PTPN11 Gene Mutation, N-RAS Gene Amplification, Neurofibromatosis 1, NF1 Mutation, CBL Gene Mutation, Monosomy 7, Chromosome Abnormality, Fetal Hemoglobin, Lymphoblastic Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult
Interventions
Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam, Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells, Thymoglobulin, Cyclophosphamide
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 60 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 23, 2026, 6:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures

NCT00884052
View directory record Official record
Conditions
Seizures, Disorder of Fetus or Newborn
Interventions
Low dose levetiracetam, High dose levetiracetam
Drug
Lead sponsor
Richard H. Haas
Other
Eligibility
1 Minute to 14 Days
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Sep 23, 2026, 6:19 PM EDT
Terminated Phase 4 Interventional Results available

Seizure Prophylaxis in Aneurysm Repair

NCT01974700
View directory record Official record
Conditions
Intracranial Aneurysms, Seizures
Interventions
Levetiracetam
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Sep 23, 2026, 6:19 PM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 23, 2026, 6:19 PM EDT